fr   en
Clinical Studies
Phase :    
Announcement :   
Select a Pharma :
Select a product :
Select a disease :
Choose date:
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [57]
Date Phase Anouncement Biotech Pharma Product Disease Country Other
2010-05-07 III Launch   Bayer Schering Pharma (Germany) regorafenib (BAY 73-4506) Regorafenib is a potent oral multi-kinase inhibitor with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases (receptors for VEGF, TIE2 receptor, RAF, RET and c-KIT) metastatic colorectal cancer North America, South America, Europe, Israel, Asia and Australia See details
2010-05-07 II-III Result Newron (italy)   ralfinamide Neuropathic low back pain (NLBP)   See details
2010-05-07 I Result Noxxon Pharma (Germany)   NOX-A12 (hematopoietic stem cell mobilizing Spiegelmer®) This Spiegelmer® binds and neutralizes the chemokine stromal cell-derived factor-1 (SDF-1, also known as CXCL12). It mobilizes hematopoietic stem cells from the bone marrow by disrupting the SDF-1 gradient that normally attracts them to their niches. Autologous stem cell transplantation Germany See details
2010-05-06 II Result Swedish Orphan Biovitrum (Sweden)   Kiobrina®(recombinant human bile-salt-stimulated lipase - rhBSSL) The rationale for adding rhBSSL to pasteurized breast milk or infant formula is to restore the natural lipase activity level that is either lost on pasteurization or totally absent in formula. enzyme replacement therapy to improve growth and development in preterm infants receiving pasteurized breast milk and/or formula   See details
2010-05-06 II Launch     EndoTag®-1 (paclitaxel encapsulated in a cationic lipid complex delivery system) triple receptor-negative breast cancer 30 centers across several European countries and in India. See details
2010-05-06 Other Launch BioInvent (Sweden) ThromboGenics (Belgium)   TB-402 (anti-factor VIII recombinant human monoclonal antibody) prophylaxis of venous thromboembolism (VTE) after knee surgery Europe See details
2010-05-03 I Launch NOXXON Pharma (Germany)   NOX-A12 (This Spiegelmer® specifically antagonizes stromal cell-derived factor-1 (SDF-1), a chemokine which attracts and activates immune- and non-immune cells. SDF-1 binds with high affinity to the chemokine receptors CXCR4 and CXCR7. The CXCR4/SDF-1 axis has been shown to play a role in stem cell mobilization, vasculogenesis, tumor growth and metastasis) cancer   See details
2010-04-30 I Launch Molecular Partners (Switzerland)   MP0112 (DARPin which inhibits all relevant forms of vascular endothelial growth factor A (VEGF-A) Wet age-related macular degeneration, Diabetic macular edema   See details
2010-04-30 I Result Endotis Pharma (France)   EP217609 (synthetic parenteral neutralizable anticoagulant) and its specific antidote avidin. EP217609 has a dual mode of action combining the properties of an indirect factor Xa inhibitor and a direct thrombin inhibitor. In addition, EP217609 can be neutralized within a few minutes after administration of avidin. EP217609 is the neutralizable version of EP42675, which has already successfully completed a Phase I program in 108 healthy subjects (See http://www.biopharmaceutiques.com/fr/tables/clinical_studies_713.html).     See details
2010-04-29 I-IIa Result TxCell (France)   OvaSave® (autologous cell therapy based on exploitation of the anti-inflammatory properties of the Tr1 regulatory lymphocyte sub-population) severe and refractory Crohn’s disease France See details
2010-04-29 III Result   Roche (Switzerland) taspoglutide (glucagon-like-peptide-1 (GLP-1) analogue) Roche exercised its licensing option for taspoglutide from Ipsen in 2006 and acquired exclusive worldwide rights to develop and market taspoglutide, except in Japan where these rights are shared with Teijin and in France where Ipsen retained co-marketing rights.     See details
2010-04-28 III Result NeuroSearch (Denmark)   Huntexil® Huntington's disease   See details
2010-04-28 I-II Result BiondVax Pharmaceuticals (Israel)   multimeric-001 vaccine (universal influenza vaccine) influenza Israel See details
2010-04-27 I Launch Debiopharm (Switzerland)   Debio 0932 (small molecule inhibitor of heat shock protein 90- Hsp 90) It was licensed-in from Curis in August 2009 (See http://www.biopharmaceutiques.com/fr/tables/agreements_623.html). advanced solid tumours; lymphoma   See details
2010-04-27 IIb Launch Paion (Germany)   CNS 7056 (water-soluble, short-acting sedative acting on GABAa receptors in the brain) sedation USA, Australia, Europe and Canada See details
[<<]      «      1   |   2   |   3   |   4   |   5   |   6   |   7   |   8   |   9   |   10   |   11      »      [57]